Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X Syndrome
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) has announced a collaboration with the FRAXA Research Foundation to test its lead asset MB204 in a preclinical model of Fragile X syndrome (FXS). FXS is a common cause of inherited intellectual disability, affecting approximately 1 in 4000 males and 1 in 8000 females. The collaboration aims to explore MB204's potential as a treatment for FXS and other forms of autism spectrum disorder.
MB204 is an adenosine A2a receptor antagonist and a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline. FRAXA will test MB204 through its internal screening program this year. The foundation previously identified BPN14770, which is currently in Phase 3 trials for Fragile X. Notably, there is currently no approved drug to treat FXS.
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ha annunciato una collaborazione con la FRAXA Research Foundation per testare il suo principale candidato MB204 in un modello preclinico di syndrome X fragile (FXS). La FXS è una causa comune di disabilità intellettiva ereditaria, che colpisce circa 1 maschio su 4000 e 1 femmina su 8000. La collaborazione mira ad esplorare il potenziale di MB204 come trattamento per la FXS e altre forme di disturbo dello spettro autistico.
MB204 è un antagonista del recettore adenosina A2a e un nuovo derivato fluorurato del farmaco anti-Parkinson approvato Istradefylline. FRAXA testerà MB204 attraverso il suo programma interno di screening quest'anno. La fondazione ha precedentemente identificato BPN14770, che attualmente è in fase 3 di sperimentazione clinica per la sindrome X fragile. È degno di nota che attualmente non esiste un farmaco approvato per il trattamento della FXS.
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ha anunciado una colaboración con la FRAXA Research Foundation para probar su activo principal MB204 en un modelo preclínico de síndrome X frágil (FXS). FXS es una causa común de discapacidad intelectual hereditaria, que afecta aproximadamente a 1 de cada 4000 hombres y 1 de cada 8000 mujeres. La colaboración tiene como objetivo explorar el potencial de MB204 como tratamiento para FXS y otras formas de trastorno del espectro autista.
MB204 es un antagonista del receptor de adenosina A2a y un nuevo derivado fluorurado del medicamento aprobado para el Parkinson, Istradefylline. FRAXA probará MB204 a través de su programa interno de selección este año. La fundación identificó previamente BPN14770, que actualmente se encuentra en ensayos de fase 3 para el síndrome X frágil. Es importante señalar que actualmente no existe un medicamento aprobado para tratar la FXS.
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF)은 FRAXA Research Foundation과 협력하여 주요 자산인 MB204를 취약 X 증후군 (FXS)의 전임상 모델에서 테스트한다고 발표했습니다. FXS는 유전적인 지적 장애의 일반적인 원인으로, 남성 4000명 중 1명 및 여성 8000명 중 1명에게 영향을 미칩니다. 이 협력의 목표는 FXS 및 기타 자폐 스펙트럼 장애에 대한 치료제로서 MB204의 잠재력을 탐색하는 것입니다.
MB204는 아데노신 A2a 수용체 길항제이며, 승인된 파킨슨병 약물인 이스트라데필린의 새로운 플루오르화 유도체입니다. FRAXA는 올해 내부 스크리닝 프로그램을 통해 MB204를 테스트할 예정입니다. 이 재단은 이전에 현재 FXS에 대해 3상 시험 중인 BPN14770을 확인했습니다. 주목할 점은 현재 FXS 치료를 위한 승인된 약물이 없다는 것입니다.
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) a annoncé une collaboration avec la FRAXA Research Foundation pour tester son actif principal MB204 dans un modèle préclinique de syndrome de l'X fragile (FXS). La FXS est une cause courante de handicap intellectuel héréditaire, touchant environ 1 homme sur 4000 et 1 femme sur 8000. Cette collaboration vise à explorer le potentiel de MB204 en tant que traitement pour la FXS et d'autres formes de troubles du spectre autistique.
MB204 est un antagoniste des récepteurs de l'adénosine A2a et un nouvel dérivé fluoré du médicament anti-Parkinson approuvé Istradefylline. La FRAXA testera MB204 via son programme de dépistage interne cette année. La fondation avait précédemment identifié BPN14770, actuellement en phase 3 d'essais cliniques pour le syndrome de l'X fragile. Il est important de noter qu'il n'existe actuellement aucun médicament approuvé pour traiter la FXS.
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) hat eine Zusammenarbeit mit der FRAXA Research Foundation angekündigt, um den führenden Wirkstoff MB204 in einem präklinischen Modell des Fragilen-X-Syndroms (FXS) zu testen. FXS ist eine häufige Ursache für vererbbare geistige Behinderung und betrifft etwa 1 von 4000 Männern und 1 von 8000 Frauen. Ziel der Zusammenarbeit ist es, das Potenzial von MB204 als Behandlung für FXS und andere Formen von Autismus-Spektrum-Störungen zu erkunden.
MB204 ist ein Antagonist des Adenosin-A2a-Rezeptors und ein neuartiges fluoriertes Derivat des genehmigten Parkinson-Mittels Istradefylline. FRAXA wird MB204 dieses Jahr im Rahmen ihres internen Screening-Programms testen. Die Stiftung hat zuvor BPN14770 identifiziert, das sich derzeit in Phase-3-Studien für Fragiles-X befindet. Es ist erwähnenswert, dass es derzeit kein zugelassenes Medikament zur Behandlung von FXS gibt.
- Collaboration with FRAXA Research Foundation to test MB204 in preclinical FXS models
- MB204 has completed pre-clinical toxicology studies and cGMP manufacturing
- Potential application of MB204 for FXS and other autism spectrum disorders
- MB204 is derived from an already approved drug (Istradefylline)
- None.
Calgary, Alberta--(Newsfile Corp. - August 13, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce it has entered a collaboration with the FRAXA Research Foundation to test its lead asset MB204 in a preclinical model (FMR1) of Fragile X syndrome (FXS).
Autism and FXS are closely related, often sharing clinical symptoms (e.g., developmental delays, challenges in social interactions, repetitive behaviors, and sensory sensitivities) and genetic mutations (e.g., FMR1). FXS is a one of the most common causes of inherited intellectual disability affecting approximately 1 in 4000 males and 1 in 8000 females. These genetic and clinical ties suggest that treatments for FXS are likely to help people with autism, Alzheimer's and other brain (neurological) conditions.
The FRAXA Research Foundation is a not-for profit organization that promotes awareness of Fragile X and supports independent pre-clinical testing of potential therapeutics through a battery of standardized tests in mouse models of FXS. FRAXA intends to test Marvel's lead asset MB204, an adenosine A2a receptor (A2aR) antagonist through its internal screening program this year. FRAXA previously identified BPN14770, which is currently in Phase 3 trials for Fragile X, initially developed by Tetra Therapeutics and later acquired by Shionogi. Of note, there is currently no approved drug to treat FXS.
"We are very interested in testing MB204 in our independent laboratories for two primary reasons," said Dr. Mike Tranfaglia, the Medical Director and co-founder of FRAXA. "First, MB204 is a novel fluorinated derivative of the approved anti-Parkinson's Disease drug Istradefylline, the latter having already been shown to be active in Fmr1 mouse models of autism. Second, MB204 has completed its pre-clinical toxicology studies and cGMP manufacturing and is at the ready for clinical testing."
"We are very grateful to be able to collaborate with FRAXA to test MB204 in their mouse models of FXS," commented Dr. Mark Williams, Chief Scientific Officer of Marvel Biosciences. "We believe MB204 is a novel potential treatment for FXS and other forms of autism spectrum disorder."
About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.
Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.
Contact Information
Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
All information contained in this news release with respect to the Company and its subsidiary, (collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219719
FAQ
What is Marvel Biosciences testing for Fragile X syndrome?
How common is Fragile X syndrome?
Are there any approved drugs for treating Fragile X syndrome?
What is the stock symbol for Marvel Biosciences Corp?
